American Thoracic Society

Asthma biologic may reduce oral steroid useA new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
First guidelines for pediatric pulmonary hypertensionPediatric pulmonary hypertension (PH) can be difficult to spot, and a lack of research on this rare condition has resulted in a lack of evidence-based diagnosis and treatment guidance–until now. The American Heart Association and the American Thoracic Society have released new, extensive guidelines that task force members hope will pave the way for new research and continued development of care plans for pediatric PH patients.
New study highlights benefits of nintedanib in IPF treatmentIIn a new long-term study, nintedanib (Ofev) improved forced vital capacity (FVC) and other idiopathic pulmonary fibrosis (IPF) symptoms. The findings were presented recently at the American Thoracic Society (ATS) 2015 International Conference in Denver.
COPD fixed-dose combo enhances lung functionBecause lung function can be substantially reduced by the time most chronic obstructive pulmonary disease (COPD) patients first see a physician, maintenance treatment should be considered at the time of diagnosis, according to new data analyses presented at the American Thoracic Society (ATS) 2015 International Conference.
Investigational dual bronchodilator improves lung function over single bronchodilators in COPDIn patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), investigational indacaterol/glycopyrronium (QVA149) bromide significantly improved lung function compared to the single bronchodilators, according to data presented at the American Thoracic Society (ATS) International Conference in Denver, May 15 to 20.
Pirfenidone reduces disease progression of IPF
Pirfenidone reduces disease progression of IPFPirfenidone (Esbriet), an oral antifibrotic therapy, was able to reduce progression of idiopathic pulmonary fibrosis (IPF) and reduce the risk of mortality, according to phase 3 trial results presented at the American Thoracic Society International Conference in San Diego.
Fixed-dose combination shows improved lung function in COPD patients: StudyThe fixed-dose combination of tiotropium and olodaterol (T+O FDC) has the potential to become a viable once-daily chronic obstructive pulmonary disease (COPD) treatment, according to data presented at the 2014 American Thoracic Society (ATS) International Conference, in San Diego.
Investigational TKI nintedanib slowed lung function loss in idiopathic pulmonary fibrosis
Investigational TKI nintedanib slowed lung function loss in idiopathic pulmonary fibrosisNintedanib, an investigational small molecule tyrosine kinase inhibitor (TKI), slowed lung function loss in patients with idiopathic pulmonary fibrosis (IPF), according to the results of 2 pivotal phase 3 trials presented at the American Thoracic Society International Conference in San Diego.
Guidelines for infant interstitial lung diseaseThe American Thoracic Society has published new guidelines on the classification, diagnosis, and management of childhood interstitial lung disease (chILD), focusing on neonates and infants aged younger than 2 years.